VitamFero moves into new laboratories for the industrial development of its veterinary vaccines
VitamFero is setting up its new facilities in the city of Angers, close to animal health industry leaders VitamFero, a French... View Article
Atlanpole Biotherapies partnering with Atlantic-Ket-Med project
Atlanpole Biotherapies cluster is a partner of the ATLANTIC KET MED European project, wich is run by Galway University of Irland... View Article
Valneva Signs $39.6 Million IXIARO® Supply Contract with US Government
Valneva SE, a fully integrated, commercial stage bioteh company focused on developing innovative, lifesaving vaccines, announces today the signing of... View Article
Horama raises €19 million in a Series B financing round
A spin-off from Philippe Mouilier’s labratory at Nantes University Hospital, Horama has been supported by Atlanpole for 5 years .... View Article
VitamFero will be presenting its immunotherapy data about infection disease prevention in chicks
These groundbreaking findings highlight the prophylactic benefits of one of VitamFero non-virulent live parasitic strains for preventing opportunistic infections in... View Article
Boost4Health : Accelerate your internationalisation
Atlanpole Biotherapies, together with 10 other leading business support organisations in 7 countries, have joined forces to enable you to... View Article
VitamFero files 3 new patent applications
Moving forward with the development of its vaccine platform, and following the results achieved with its avian influenza vaccine candidate... View Article
Biomedical Tissues raises €500K for the marketing and commercialisation of its landmark product – Tisseos®
Biomedical Tissues, Atlanpole Biotherapies member and a medtech company, completed a €0.5 million capital increase over the summer. The funds... View Article
In-Cell-Art : Pass trough new steps for their Nanotaxi®
In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® designed to unlock the promise of nucleic acids to... View Article
Association of OSE Immunotherapeutics with GERCOR
OSE Immunotherapeutics Partners with Oncology Physician Network GERCOR to Conduct a Combination Phase 2 Trial of Tedopi® for Pancreatic Cancer.... View Article